Related Experiment Video
Updated: Jun 18, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antiplatelets and stroke outcomes: state of the science
1Sharp Memorial Hospital, Ortho/Neuro Services, 7901 Frost Street, San Diego, CA 92123, USA. dawn.matherne@sharp.com
Abstract:
This article reviews the current use of antiplatelet medications in secondary stroke prevention and in acute stroke treatment. Antiplatelet medications prevent emboli and thrombus formation to avert further vascular occlusion and ischemia. Aspirin, clopidogrel (Plavix), and extended release aspirin/dipyridamole (Aggrenox) represent the mainstay of secondary prevention of ischemic and transient ischemic stroke. Although antiplatelet medications prevent platelet aggregation by different mechanisms, the end result is a significantly decreased risk of secondary stroke, myocardial infarction, and death. Increasingly, the literature reflects hypotheses about the potential utility of aspirin and clopidogrel antiplatelet therapy as a preventative measure in patients at risk of stroke and as an approach to treat embolic ischemic stroke in the acute phase once it has occurred.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Atherosclerosis III: Management
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
